United States

Dr.Reddy's Laboratories Ltd (REDY.BO)

REDY.BO on Bombay Stock Exchange

19 Jan 2018
Change (% chg)

Rs21.85 (+0.89%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

India's Dr Reddy's expects U.S. "adverse pricing environment" to persist
Thursday, 27 Jul 2017 09:54am EDT 

July 27 (Reuters) - India's Dr Reddy's Laboratories ::COO Abhijit Mukherjee says expects adverse pricing environment in U.S. to persist.COO Mukherjee says "remain optimistic on 2-3 launches per quarter" in U.S..India's Dr Reddy's labs COO Mukherjee says experiencing "a lot of transition challenges" due to GST.Dr Reddy's Labs exec says improving manufacturing processes and automating procedures will take a few more quarters to complete.  Full Article

Dr.Reddy's Laboratories, CHD Bioscience announce global license & commercialization deal
Thursday, 27 Jul 2017 06:55am EDT 

July 27 (Reuters) - Dr.Reddy's Laboratories Ltd :Co, CHD Bioscience announce global license & commercialization deal for phase III clinical trial candidate for mitigation of surgical site infections.Co to get equity in CHD valued at $30 million on IPO of CHD or minimum of $30 million in cash in 18 months of execution of agreement.Says will also receive additional milestone payments of $40mln upon USFDA approval.  Full Article

Dr.Reddy's Laboratories June-qtr consol profit falls about 57 pct
Thursday, 27 Jul 2017 04:43am EDT 

July 27 (Reuters) - Dr.Reddy's Laboratories Ltd :June quarter consol net profit after tax and share of profit of associates 666 million rupees versus profit of 1.54 billion rupees last year.Says Q1 results of FY18 "been below expectations".Dr.Reddy's Laboratories-headwinds as price erosion due to U.S. customer consolidation continue.Consol june quarter total revenue from operations 33.33 billion rupees versus 32.45 billion rupees last year.Lower contribution from new product launches in U.S. and GST in India also impacted performance in quarter.  Full Article

Dr.Reddy's Labs says audit of Mexican plant by USFDA completed with zero observations
Friday, 21 Jul 2017 01:27am EDT 

July 21 (Reuters) - Dr.Reddy's Laboratories Ltd :Says audit of our API Cuernavaca plant at Mexico, by US FDA, has been completed with zero observations.  Full Article

Dr.Reddy's Labs recalls Cipla-made zenatane capsule from U.S. markets
Thursday, 15 Jun 2017 02:03am EDT 

June 15 (Reuters) - Dr.Reddy's Laboratories Ltd :Dr.Reddy's Laboratories clarifies on news item, "Dr Reddy's recalls 3.25l cartons Cipla-made acne drug from US"..Says voluntarily recalled Cipla-made zenatane capsule from US markets.Recall of prodcuts is a usual activity in normal course of business operations.Says overall impact on co's financials of recall not likely to be significant.  Full Article

Dr.Reddy's Labs gets EIR as closure of audit of Miryalaguda API manufacturing plant
Tuesday, 13 Jun 2017 11:05pm EDT 

June 14 (Reuters) - Dr.Reddy's Laboratories Ltd :Says got EIR after audit of API manufacturing plant at Miryalaguda, by US FDA, as closure of audit.  Full Article

Dr.Reddy's Laboratories announces launch of Bivalirudin for injection in U.S. market
Tuesday, 6 Jun 2017 01:48am EDT 

June 6 (Reuters) - Dr.Reddy's Laboratories Ltd :Says announces launch of Bivalirudin for injection in U.S. market.  Full Article

Dr.Reddy's Labs' audit of formulations Srikakulum plant Unit II completed with zero observations
Thursday, 25 May 2017 08:32am EDT 

May 25 (Reuters) - Dr.Reddy's Laboratories Ltd :Says audit of formulations Srikakulum Plant unit II, Andhra Pradesh by US FDA, completed with zero observations..  Full Article

Dr.Reddy's Laboratories says USFDA approved launch of doxorubicin hydrochloride liposome injection in U.S.
Wednesday, 17 May 2017 03:15am EDT 

May 17 (Reuters) - Dr.Reddy's Laboratories Ltd :Announces USFDA approval for launch of doxorubicin hydrochloride liposome injection in U.S. Market.  Full Article

India's Dr.Reddy's Laboratories March-qtr consol profit rises about three-fold
Friday, 12 May 2017 03:40am EDT 

May 12 (Reuters) - Dr.Reddy's Laboratories Ltd :Consol March quarter net profit 3.38 billion rupees.Consensus forecast for March quarter consol profit was 4.27 billion rupees.Consol March quarter net sales 34.99 billion rupees.Consol net profit in March quarter last year was 1.23 billion rupees as per Ind-AS; net sales 36.95 billion rupees.Recommended final dividend of 20 rupees per share.Says "FY17 has been a challenging year due to lack of new product approvals for US market".  Full Article

BRIEF-Dr.Reddy's Laboratories Launches Melphalan Hydrochloride Injection In U.S.

* SAYS LAUNCH OF MELPHALAN HYDROCHLORIDE FOR INJECTION IN U.S. MARKET Source text - http://bit.ly/2C8souU Further company coverage: